TheDinarian
News • Business • Investing & Finance
How Rockefeller Monopolized Medicine and Created BIG PHARMA
Please read and share, let the truth be known worldwide...
October 13, 2023
post photo preview

Born in 1839, John D. Rockefeller would go on to become one of the great robber barons and industrialist tycoons of American history. By the turn of the 20th century, Rockefeller controlled 90% of the oil refineries in the US through his company Standard Oil, becoming in the process America’s first billionaire.

Of course, in 1911, Standard Oil was ruled by the US Supreme Court to be an illegal monopoly in violation of antitrust laws and forced to break up. Like his father, John D. Rockefeller had built his success on illegality, cons, and scams.

Still, this was not enough for Rockefeller. He wanted more.

 

How Rockefeller Targeted Medicine

At the time, chemicals made from oil, known as ‘petrochemicals,’ were being discovered and developed in the US. This included the discovery that pharmaceutical drugs could be made from oil, which Rockefeller saw as an opportunity to expand his empire. The key was that petrochemicals, unlike natural health remedies, could be patented, presenting an enormous opportunity for Rockefeller profits.

There was only one problem – at the time, natural, herbal, and traditional medicines were very popular in the US. Something like half of the doctors and medical colleges in the country were using holistic medicine, natural remedies, and knowledge taken from Indigenous Native Americans. Rockefeller needed a way to eliminate the competition, to create a monopoly in medicine as he had done with oil.

And so, he went to his good friend Andrew Carnegie, another robber baron who had gotten rich through his monopoly of the steel industry and, incidentally, one of the country’s leading eugenicists. Together, the two men hatched a plan to take over American medicine.


maxresdefault.jpg

 

The Creation of Big Pharma

From the cover of the Carnegie Foundation, they would send a man named Abraham Flexner around the country to report on its medical colleges and hospitals. After visiting all 155 medical schools existing at that time in the US and Canada, he completed the seminal Flexner Report in 1910.

Following the directions of his employers, Flexner called in his report for a total restructuring of the American medical system, most specifically, for the pushing aside of natural and traditional remedies in favor of Rockefeller pharmaceuticals. The report even specifically mentioned the eradication of “dissidents,” appropriately, since this is exactly what happened.

Almost immediately after the report was issued, medical schools teaching things like naturopathy, homeopathy, electromagnetic field therapy, and so on, were told to drop these things or close. More than half of all medical colleges in the country did close, and many non-compliant doctors were demonized and even jailed.

But Rockefeller and Carnegie went further, offering huge grants to medical schools and hospitals so long as they only taught and practiced Rockefeller medicine, and allowed Rockefeller agents on their boards of directors to ensure compliance.

It was the carrot and the stick – those who agreed got funded with big money, those who didn’t were crushed.

In this way, all medical colleges in the country were streamlined and homogenized, with doctors all learning the same thing – how to use and prescribe Rockefeller’s patented drugs.

But, like any good monopolist, Rockefeller went further in seeking to consolidate his control. He took over the AMA and emboldened it as the gatekeeper of scientific thought and witch hunter of alternative medical practices. He took control of the FDA in order to control the approval process for new drugs. He even founded the American Cancer Society in 1913. Within a few short years, Rockefeller was in total control of the American medical system in both thought and action.

The result of this takeover, the product of this monopolist son of a conman and his eugenicist partner, would become known as “Big Pharma.”

That Big Pharma took over and monopolized American medicine, promoting their own patented, profit-making products and suppressing all others, isn’t even a conspiracy theory.

In fact, it was recorded for all to see in 1953 …

 

The Fitzgerald Report

In the early 1950s, US Senator Charles Toby enlisted an investigator with the Interstate Commerce Commission named Benedict Fitzgerald to examine allegations of conspiracy and monopoly in medicine. Toby had become interested in the issue after his own son had gotten cancer and been given less than two years to live by orthodox medicine before pursuing alternative treatments and being cured.

The resulting 1953 report, known as the Fitzgerald Report, was truly shocking. It concluded that Big Pharma had been involved in “a conspiracy of alarming proportions.”

First, there was

“The organized effort to hinder, suppress and restrict the free flow of drugs which allegedly proven successful in cases where clinical records, case history, pathological reports, and x-ray photographic proof, together with the alleged cured patients, are available.”

On top of that,

“Public and private funds have been thrown around like confetti at a country fair to close up and destroy clinics, hospitals, and research laboratories which do not conform to the viewpoint of medical associations.”

The report even noted that Big Pharma had conspired to suppress at least 12 promising cancer treatments, including mentioning Hoxsey Therapy by name.

It was an unfathomably damning report, making clear that the tentacles of a Big Pharma conspiracy to suppress alternative medicine were everywhere.

But as it turns out, the report did not go far enough

 

The Suppression of Laetril as a Cure for Cancer

Oftentimes when a new natural cancer treatment appears, the assertion from the medical establishment is that the new treatment is either unproven, or disproven. There is no better example of what this really means in the era of Big Pharma than the case of a cancer treatment called Laetrile.

In 1952, a year before the Fitzgerald Report, a biochemist named Ernst Krebs proposed that cancer was a deficiency disease which could be cured with a compound called amygdalin, found in over 1,200 plants, and most specifically in the seeds of apricots. By extracting this amygdalin from apricot kernels, Krebs created a product he called Laetrile.

Over the course of many years, Krebs conducted numerous lab experiments on animals which showed that Laetrile was an effective cancer treatment, that somehow, it caused cancer cells to self-destruct.

By the 1960s, a doctor named John Richardson had picked up the research, and had even begun treating human patients with Laetrile. Unsurprisingly, the Rockefeller-controlled FDA launched a massive media campaign against Richardson and Laetrile, claiming that the treatment was toxic and dangerous. By 1971, the FDA officially banned Laetrile, and, in 1972, they stormed Richardson’s clinic and arrested him.

But even after Richardson was jailed, people kept asking about Laetrile, writing to government officials, medical journals, and scientific labs demanding answers. At this point, Big Pharma knew they had to put their foot down once and for all. They needed to undertake official testing which proved that Laetrile didn’t work.

The testing would take place at Memorial Sloan-Kettering Cancer Center in New York City, and what would happen next would come to be described as “one of the biggest medical cover-ups the world of cancer research has ever seen.”

The tests would be led and directed by Dr. Kanematsu Sugiura, known at that time as “the preeminent cancer researcher in America.” He had over 60 years of experience, publishing hundreds of academic papers on the subject. As one scientist said, “When Dr. Sugiura publishes, we know we don’t have to repeat the study, for we would obtain the same results he has reported.”

In 1972, testing began, with Laetrile being administered to mice with many different types of cancerous tumors. At its completion, Dr. Sugiura concluded that Laetrile stopped the spread of cancer, inhibited the growth of tumors, and acted as a cancer prevention. It even provided relief from pain and improved general health.

This seemed to be incredible news. Except, there were three Rockefellers sitting on the board of Sloan-Kettering, as well as a dozen more people representing companies making big money from Big Pharma. When they caught word of the test results, “all hell broke loose,” and another round of tests was ordered.

Unfortunately for Sloan-Kettering executives, the second round of testing only confirmed the first. Except this time, with two confirmed tests from the legendary Dr. Sugiura in the books, mainstream media was forced to cover it. Had a cure for cancer really been found, they asked?

Sloan-Kettering officials refused to speak with the media, refused to discuss the results or answer any questions, saying only in a prewritten statement that a third round of tests had been ordered in order to “clarify” the results, as if they had not been twice clarified already.

In this third test, a new wrinkle would be introduced – Dr. Sugiura would be blinded. He would not know which half of the mice would be receiving Laetrile, and which half would be given a saline solution, as if this eminently respected scientist was going to somehow manipulate the results.

After four weeks, Dr. Sugiura could see which of the mice were being given Laetrile, since mice in some of the cages had fewer and smaller tumors, while mice in the other cages showed no effects. Sloan-Kettering overseers who were supervising the project confirmed to Dr. Sugiura that he was correct. For a third time, Laetrile’s cancer treating properties were confirmed.

Except, arguing that Dr. Sugiura was no longer blinded since he knew which cages were which, Sloan-Kettering officials shut the tests down.

They would try yet again to get the results they were looking for with a fourth test. This time, not only would Dr. Sugiura be blinded, but the mice who were receiving the treatment would be mixed together with those who weren’t. Dr. Sugiura warned that this was dangerous because there was no dependable way to ensure the lab techs administering the treatment would be able to identify the correct mice every time. And, in fact, this is exactly what happened. Some of the mice who were purportedly only being given a saline solution saw their tumors stop growing.

“There’s something funny here,” Dr. Sugiura professed. The ‘something funny’ was that the treatments had been mixed, with many mice receiving some Laetrile and some saline solution, just as Dr. Sugiura had predicted.

Yet, in this case, the legitimacy of the results wasn’t important to Sloan-Kettering’s Rockefeller board. Immediately, they announced that “results from the experiment do not confirm the earlier positive findings of Sugiura.”

Then, they called a press conference attended by most of mainstream media and declared, “Laetrile was found to possess neither preventive, nor tumor-regressant, nor anti metestatic, nor curative anti-cancer activity” – the exact opposite of what the first three tests had shown.

At the end of the press conference, the floor was opened to questions from the media, which is when things took a dramatic turn.

“Dr. Sugiura,” someone shouted, “Do you stick by your belief that Laetrile stops the spread of cancer?”

The room fell silent as the fabled Dr. Sugiura rose to his feet and replied, “I stick.”

The next month, Sloan-Kettering executives appeared before a Senate subcommittee hearing to decide the fate of Laetrile. While it had been banned by the FDA in 1971, some states were challenging this decision.

At the hearing, Sloan-Kettering executives asserted, “There is not a particle of scientific evidence to suggest that Laetrile possesses any anti-cancer properties at all” totally ignoring the three full lab tests of scientific evidence from “the preeminent cancer researcher in America.” As a result of the testimony, Laetrile was officially banned nationwide by 1980.

Afterwards, Dr. Sugiura was asked why Sloan-Kettering was so against Laetrile. “I don’t know,” he replied, “Maybe the medical profession doesn’t like it because they are making too much money.”

When Big Pharma says an alternative treatment has been disproven, this is what they mean.

 

Is Big Pharma Suppressing Information for Profit?

But what about if tests were not done in a Rockefeller-controlled lab. What if one were to do their own tests, build their own case studies, and present them to the appropriate authorities themselves?

One man provided an answer.

Stanislaw Burzynski was a Doctor of Biochemistry who immigrated to the US from Poland in 1970, where he took up a position as a researcher and assistant professor at Baylor University in Houston, Texas. There, he discovered something which he called antineoplastons – naturally occurring “molecular switches” in the human body which, Burzynski asserted, the body used to control cancer growth.

At first, Burzynski’s discoveries were well received by colleagues. In fact, so impressive was his work that he was offered a tenured position in Baylor’s Department of Pharmacology. He should have been thrilled, yet Burzynski knew that if he accepted, he would lose his independence as a researcher. So, he refused the position, instead choosing to found the Burzynski Research Institute in order to continue his work. On his way out the door at Baylor, his boss warned him, “Just wait, Burzynski. They’re going to kick your ass.”

In short order, Burzynski and his clinic were investigated by local medical authorities for using “unapproved medications,” while the Rockefeller-founded American Cancer Society put antineoplastons on its “unproven methods” list, and those who had been funding his research pulled their support.

In 1983, the FDA filed a lawsuit to get him to shut down his operation, and when this failed, FDA agents and federal marshals simply raided the Burzynski Research Institute and seized over 200,000 confidential documents.

Still Burzynski continued on. He raised millions of dollars through his Institute to pay for clinical trials for antineoplastons, money Big Pharma companies are more than happy to spend since they know they will recoup it when their products are patented. By the mid-90s, he was able to provide the FDA with sixty clinical trials, meeting the requirement for their Phase I testing.

For another decade he worked, compiling hundreds more clinical trials, meeting the requirements for Phase II of testing on his own at the cost of millions of dollars.

In 2011, Burzynski began Phase III testing, which involves thousands of participants and can last for years, again, at the cost of many millions of dollars. He was closing in on the finish line by 2013, which is when the FDA stepped in and put a stop to the trials. Their reason? They complained that the Burzynski Research Institute was doing all of the testing, when, of course, this is simply how the FDA approval process works. The only difference is usually the testing is being done by a Big Pharma company.

Finally, in 2017, the FDA cancelled antineoplaston clinical trials for good, refusing Burzynski the right to even conduct the tests. Moreover, Burzynski had his medical license revoked and was fined hundreds of thousands of dollars for his trouble.

The point made by Burzynski and his antineoplastons, by Sloan-Kettering’s Laetrile trials, is simple. It’s a case of ‘you’re damned if you do and damned if you don’t.’ If testing is conducted in a Rockefeller Big Pharma laboratory, it will be repeated and repeated and repeated until it gives the desired results, no matter how manipulated these results might be. And if you conduct the tests yourself, spending millions upon millions of dollars, the results will still not be accepted.

03-04-burzynski-02.webp?w=600&q=75&f=aa0b9051be2d61eaa37d43d89e96624f
Over 60 patients defended Dr. Burzynski stating they were cured by him.

Big Pharma controls the testing, they control approval, they control academic thought. But look closer, and it goes even further than that.

Big Pharma employs 1,270 registered lobbyists in the halls of government, more than two Big Pharma lobbyists for every member of congress, at a cost of over $200 million per year. They also spend tens of millions of dollars every year financing political campaigns – nearly every member of congress is funded by Big Pharma. On top of that, Big Pharma lobbyists and executives are repeatedly put in charge of the government bodies tasked with overseeing the pharmaceutical industry, like the FDA. Simply, the production and sale of medicine is tightly regulated by government, and Big Pharma controls the government.

Is it really so hard to believe that Big Pharma would use its control of academia, science, and government, to suppress valuable information for their own profit?

In reality, suppressing truth for profit is as American as apple pie – from the 1950s, when tobacco companies fought to suppress lung cancer knowledge as people died, to modern times, when oil companies insist that the debate around climate change is still ongoing, even as the consequences scientists promised decades ago are all around.

But pharmaceutical companies? Those purportedly tasked with providing health? Would they really suppress a cure for cancer? And kill people?

Actually, that Big Pharma would knowingly and intentionally kill people for profit is not conspiracy, it is established fact, admitted on record in American courts.

 

How Big Pharma Created the American Opioid Crisis

In October of 2020, Big Pharma flagbearer Purdue Pharma pled guilty in court to criminal charges for its role in the American opioid crisis, agreeing to pay some $8.3 billion in the settlement.

Opioids were a new type of synthetic pain medication that emerged in the early-1990s, which Big Pharma companies like Purdue aggressively promoted while suppressing information about the dangers, most specifically, the extreme addictiveness. Today, not only is chronic pain more prevalent than ever in the US, but nearly a million people have died from opioid overdoses, and another 3 million have fallen victim to addiction.

In pleading guilty at trial, Purdue Pharma admitted on record to having supplied drugs “without legitimate medical purpose.” In other words, the purpose of opioids wasn’t medical, it wasn’t to cure pain; it was to get people addicted so they’d buy more. Purdue even admitted to paying off health insurance companies to deny coverage for alternative care, forcing people to take opioids, and paying off doctors to overprescribe their product to patients.

depositphotos_178773006-stock-photo-macro-of-oxycodone-opioid-tablets.jpg

By February of 2022, four more of the largest Big Pharma companies had reached a $26 billion settlement for their own role in the crisis. These, along with Purdue, are the largest and most powerful pharmaceutical companies in the country, the ones who lobby governments and sit on medical boards. And here they are, on the record, poisoning people for profit.

 

Chemotherapy - The Only Legal "Cure" for Cancer

Apply this knowledge to cancer specifically, and think about what chemotherapy is.

The treatment was first conceptualized by doctors examining soldiers who had been exposed to mustard gas during World War II. Noticing that mustard gas had toxic effects on the blood cells of soldiers, doctors surmised that it could be used against cancer cells.

This was how the first version of chemotherapy, and model for all subsequent versions, was created, from a compound used as an agent of chemical warfare. This is what Big Pharma is telling cancer patients to put in their body.

Of course, it is no big secret that chemotherapy is toxic. Cancer patients are warned that side effects can include everything from vomiting and nausea, to infertility, to organ damage, and even death. They are even warned it can lead to a “second cancer.” In other words, patients are told chemotherapy might treat their cancer, but that it might also cause cancer; it might save their life, but it might also kill them. As one former president of the American Chemical Society succinctly put it, “chemotherapy does much, much more harm than good.”

A bit like opioids …

But that’s the point; there are no profits in the cure. Big Pharma needs people sick, so that people need more and more expensive “treatment.”

In this, the era of Big Pharma is alone in the history of medicine …

Link

The Dinarian On Locals is a labor of love that I pour my heart and soul into during my personal time. Countless hours are dedicated to delivering you the most up-to-date, unfiltered, and authentic news and information. Your support means the world to me, and I invite you to consider making a donation or becoming a dedicated supporter of this project. Any amount of XRP donations can be sent by scanning the QR code below and are greatly appreciated. ~ Namaste🙏🏼The Dinarian

 

 

community logo
Join the TheDinarian Community
To read more articles like this, sign up and join my community today
1
What else you may like…
Videos
Podcasts
Posts
Articles
Top finance executive says crypto will eventually become the global reserve currency

Top finance executive says crypto will eventually become the global reserve currency and new technology will surpass Bitcoin while eliminating friction in finance.

00:02:54
The GENIUS Act, how it affects your investments 👀

The GENIUS Act becomes effective January 18th, 2027.

It establishes a stablecoin framework.

Banks can now issue stablecoins.
Non-banks can technically get permits, but it's extremely difficult.

Why this matters now:

The government is still running deficits and printing money,
They need buyers for the new debt they're constantly issuing (Treasury bonds).

The problem is that foreign buyers have been pulling back and buying less US debt.

By requiring stablecoins to be backed by "reserve assets" (which includes US government debt/Treasuries), the government essentially creates a new mandatory buyer for their debt.

Every stablecoin issued means someone has to buy Treasury bonds to back it.

So it’s a way to not pay not down their existing debt—but ensure there's demand to finance their ongoing deficit spending.

However, here’s the problem.

There's a kill switch built in.

Section 126 requires all issuers to have technical capability to freeze, seize, or burn stablecoins when legally required.

It's not ...

00:02:46
PRECIOUS METALS ARE SURGING—AND THE REASONS SHOULD WORRY WASHINGTON 📉🇺🇸

The financial landscape is shifting rapidly. Gold has hit all-time highs, and Silver has nearly doubled since May, skyrocketing from $38 to over $74/oz. 🥈🚀

What’s driving the surge?

🔹 De-Dollarization: Countries are actively moving away from the USD. 🌍💸

🔹 Exploding Debt: Confidence in the U.S. financial system is eroding as debt spirals. 📈📉

🔹 Geopolitical Leverage: Starting Jan 1, China will require licenses to export silver, tightening an already strained market. 🇨🇳📦

Silver isn't just money; it's the lifeblood of the Green Energy transition (Solar, EVs, Electronics). 🔋☀

When trust in paper evaporates, the world returns to what has worked for thousands of years: Tangible Assets. Gold and silver cannot be printed or frozen. 🥇🥈

The competition for scarce resources has officially begun. 🏁💎

(Source: @BankerWeimar)

00:00:40
👉 Coinbase just launched an AI agent for Crypto Trading

Custom AI assistants that print money in your sleep? 🔜

The future of Crypto x AI is about to go crazy.

👉 Here’s what you need to know:

💠 'Based Agent' enables creation of custom AI agents
💠 Users set up personalized agents in < 3 minutes
💠 Equipped w/ crypto wallet and on-chain functions
💠 Capable of completing trades, swaps, and staking
💠 Integrates with Coinbase’s SDK, OpenAI, & Replit

👉 What this means for the future of Crypto:

1. Open Access: Democratized access to advanced trading
2. Automated Txns: Complex trades + streamlined on-chain activity
3. AI Dominance: Est ~80% of crypto 👉txns done by AI agents by 2025

🚨 I personally wouldn't bet against Brian Armstrong and Jesse Pollak.

👉 Coinbase just launched an AI agent for Crypto Trading
Silver Is Holding Strong At $80

All of the silver mining around the world produces about 820 million oz per year, and it is declining.

Recycling (jewelry, silverware, some e-waste) produces 190 million oz per year.

Global demand for silver is about 1.2 billion oz per year. That is the problem. Demand exceeds supply by 100-200 million oz per year and there is not enough extra silver in vaults to handle it anymore.

And now China is starting export restrictions on January 1, 2026. 🚀 🥈

post photo preview
Intensifying Shortage: This Is What A Run On The London Silver Market Looks Like

Dutch trading specialist Karel Mercx posted the following commentary where the opposite (multiply by -1) of the silver swap rate minus US interest rates can be used as a proxy for the implied silver lease rate to determine physical shortage in the London silver market.:

“The 1-year silver swap minus the US interest rate is now –7.18%.

That distortion explains why the silver rally is not over.

Only at the red line do supply and demand normalize.”
https://www.zerohedge.com/markets/intensifying-shortage-what-run-london-silver-market-looks

Oops, There's An Alien In Your Religion (Clif High)
post photo preview
Stellar CEO Reveals Where Real Opportunity Lies in Crypto Market: Details

In a recent tweet, Stellar Development Foundation (SDF) CEO and Executive Director Denelle Dixon defines what "real opportunity" is in blockchain as a new financial future beckons.

The SDF CEO was reacting to a recent Bloomberg report on Bank of New York Mellon Corp (BNY), Nasdaq, S&P Global and iCapital participation in a new $50 million investment round by Digital Asset Holdings. This comes as some of Wall Street’s biggest names embrace the technology that underpins cryptocurrencies to handle traditional assets.

Reacting to this development, Stellar Foundation CEO Denelle Dixon stated that every blockchain investment is a bet on a different financial future. Dixon added that seeing banks explore blockchain technology validates what has been known over the years.

Real opportunity defined

While Wall Street’s biggest names betting on blockchain might be one of the most significant adoption milestones in the digital asset market, Dixon defines what real opportunity is and what it is not.

According to the SDF executive director, real opportunity is not replicating old systems on new rails but rather building open networks that fundamentally expand global finance participation.

"But the real opportunity isn’t replicating old systems on new rails—it’s building open networks that fundamentally expand who gets to participate in global finance. That’s the opportunity," Dixon tweeted.

At the Meridian 2025 event, Stellar outlined its long-term privacy strategy, committing to investing in critical privacy infrastructure and building foundational cryptographic capabilities.

Stellar eyes privacy upgrade

A new protocol upgrade is on the horizon for the Stellar network: X-Ray, which lays the groundwork for developers to build privacy applications on Stellar using zero-knowledge (ZK) cryptography.

The protocol timeline testnet vote is anticipated for Jan. 7, 2026, while the mainnet vote is expected for Jan. 22, 2026.

Source

  🙏 Donations Accepted, Thank You For Your Support 🙏

If you find value in my content, consider showing your support via:

💳 Stripe:
1) Visit http://thedinarian.locals.com/donate

💳 PayPal: 
2) Simply scan the QR code below 📲 or Click Here

🔗 Crypto Donations Graciously Accepted👇
XRP: r9pid4yrQgs6XSFWhMZ8NkxW3gkydWNyQX
XLM: GDMJF2OCHN3NNNX4T4F6POPBTXK23GTNSNQWUMIVKESTHMQM7XDYAIZT
XDC: xdcc2C02203C4f91375889d7AfADB09E207Edf809A6

Read full Article
post photo preview
XDC Network's acquisition of Contour Network

XDC Network's acquisition of Contour Network marks a silent shift to connect the digital trade infrastructure to real-time, tokenized settlement rails.

In a world where cross-border payments still take days and trap trillions in idle liquidity, integrating Contour’s trade workflows with XDC Network Blockchains' ISO 20022 financial messaging standard to bridge TradFi and Web3 in Trade Finance.

The Current State of Cross-Border Trade Settlements

Cross-border payments remain one of the most inefficient parts of global finance. For decades, companies have inter-dependency with banks and their correspondent banks across the world, forcing them to maintain trillions of dollars in pre-funded nostro and vostro balances — the capital that sits idle while transactions crawl across borders.

Traditional settlement is slow, often 1–5 days, and often with ~2-3% in FX and conversion fees. For every hour a corporation can’t access its own cash increases the cost of financing, tightens liquidity that could be used for other purposes, which in turn slows economic activity.

Before SWIFT, payments were fully manual. Intermediary banks maintained ledgers, and reconciliation across multiple institutions limited speed and volume.

SWIFT reshaped global payments by introducing a secure, standardized messaging infrastructure through ISO 20022 - which quickly became the language of money for 11,000+ institutions in 200 countries.

But SWIFT only fixed the messaging — not the movement. Actual value still moves through slow, capital-intensive correspondent chains.

Regulated and Compliant Stablecoin such as USDC (Circle) solves the part SWIFT never could: instant, on-chain settlement.

Stablecoin Settlement revamping Trade and Tokenization

Stablecoin such as USDC is a digital token pegged to the US Dollar, still the most widely used currency for trade, enabling the movement of funds instantly 24*7 globally - transparently, instantly, and without the need for any intermediaries and the need to lock in trillions of dollars of idle cash.

Tokenized settlement replaces multi-day reconciliation with on-chain finality, reducing:

  • Dependency on intermediaries
  • Operational friction
  • Trillions locked in idle liquidity

For corporates trapped in long working capital cycles, this is transformative.

Digital dollars like USDC make the process simple:

Fiat → Stablecoin → On-Chain Transfer → Fiat

This hybrid model is already widely used across remittances, payouts, and treasury flows.

But one critical piece of global commerce is still lagging:

👉 Trade finance.

The Missing link is still Trade Finance Infrastructure.

While payments innovation has raced ahead, trade finance infrastructure hasn’t kept up. Document flows, letters of credit, and supply-chain financing remain siloed, paper-heavy, and operationally outdated.

This is exactly where the next breakthrough will happen - and why the recent XDC Network acquisition of Contour is a silent revolution.

It transforms to a new era of trade-driven liquidity through an end-to-end digital trade from shipping docs to payment confirmation – one infrastructure that powers all.

The breakthrough won’t come from payments alone — it will come from connecting trade finance to real-time settlement rails.

The XDC + Contour Shift: A Silent Revolution

  • Contour already connects global banks and corporates through digital LCs and digitized trade workflows.
  • XDC Blockchain brings a settlement layer built for speed, tokenization, and institutional-grade interoperability and ISO 20022 messaging compatibility

Contour’s digital letter of credit workflows will be integrated with XDC’s blockchain network to streamline trade documentation and settlement.

Together, they form the first end-to-end digital trade finance network linking:

Documentation → Validation → Settlement all under a single infrastructure.

XDC Ventures (XVC.TECH) is launching a Stable-Coin Lab to work with financial institutions on regulated stablecoin pilots for trade to deepen institutional trade-finance integration through launch of pilots with banks and corporates for regulated stable-coin issuance and settlement.

The Bottom Line

Payments alone won’t transform Global Trade Finance — Trade finance + Tokenized Settlement will.

This is the shift happening underway XDC Network's acquisition of Contour is the quiet catalyst.

Learn how trade finance is being revolutionised:

https://www.reuters.com/press-releases/xdc-ventures-acquires-contour-network-launches-stablecoin-lab-trade-finance-2025-10-22/

Source

🙏 Donations Accepted, Thank You For Your Support 🙏

If you find value in my content, consider showing your support via:

💳 Stripe:
1) or visit http://thedinarian.locals.com/donate

💳 PayPal
2) Simply scan the QR code below 📲 or Click Here

🔗 Crypto Donations Graciously Accepted👇
XRP: r9pid4yrQgs6XSFWhMZ8NkxW3gkydWNyQX
XLM: GDMJF2OCHN3NNNX4T4F6POPBTXK23GTNSNQWUMIVKESTHMQM7XDYAIZT
XDC: xdcc2C02203C4f91375889d7AfADB09E207Edf809A6

 

Read full Article
post photo preview
Inside The Deal That Made Polymarket’s Founder One Of The Youngest Billionaires On Earth🌍

One year ago, the FBI raided Polymarket founder Shayne Coplan’s apartment. Now, the college dropout is a billionaire at age 27.

In July, Jeffrey Sprecher, the 70-year-old billionaire CEO of Intercontinental Exchange, the parent company of the New York Stock Exchange, sat at Manhatta, an upscale restaurant in the financial district overlooking the sprawling New York City skyline from the 60th floor. As a sommelier weaved through tables pouring wine, in walked Shayne Coplan—in a T-shirt and jeans, clutching a plastic water bottle and a paper bag with a bagel he’d picked up en route. Sprecher chuckles as he recalls his first impression of the boyish, eccentric entrepreneur: “An old bald guy that works at the New York Stock Exchange, where we require that you wear a suit and tie, next to a mop-headed guy in a T-shirt that's 27.” But Sprecher was fascinated by Polymarket, Coplan’s blockchain-based prediction market, and after dinner, he made his move: “I asked Shayne if he would consider selling us his company.”

Prediction markets like Polymarket let thousands of ordinary people bet on future events—the unemployment rate, say, or when BitCoin will hit an all-time high. In aggregate, prediction market bets have proven to be something of a crystal ball with the wisdom of the crowd often proving itself more prescient than expert opinion. For instance, Polymarket punters predicted that Trump would prevail in the 2024 presidential election, when many national pundits were sure that Kamala Harris would win.

Coplan initially turned down Sprecher’s buyout offer. But discussions led to negotiations and eventually a deal. In October, Intercontinental announced it had invested $2 billion for an up to 25% stake in the company, bringing the young solo founder the balance he was looking for. “We're consumer, we’re viral, we're culture. They’re finance, they’re headless and they’re infrastructure,” Coplan tells Forbes in a recent interview.

At the same time, Coplan announced investments from other billionaires including Figma’s Dylan Field, Zynga’s Mark Pincus, Uber’s Travis Kalanick and hedge fund manager Glenn Dubin. A longtime Red Hot Chili Peppers fan, Coplan even convinced lead singer Anthony Kiedis to invest after a mutual acquaintance brought the musician to Coplan’s apartment one day. “He's buzzing my door, and I’m like, ‘holy shit,'” Coplan recalls, his bright blue eyes widening. “I love their music. A lot of the inspiration [for my work] comes from the music that I listen to.”

Thanks to the deals, Polymarket’s valuation quickly shot to $9 billion, making the 2025 Under 30 alum the world’s youngest self-made billionaire, with an estimated 11% stake worth $1 billion. His reign was short: twenty days later, he was overtaken as the youngest by the three 22-year-old founders of AI startup Mercor.

Young entrepreneurs are minting ten-figure fortunes faster than ever. In addition to the Mercor trio and Coplan, 15 other Under 30 alumni—including ScaleAI cofounder Lucy Guo, Reddit’s Steve Huffman and Cursor’s cofounders—became billionaires this year, while Guo’s cofounder Alexandr Wang and Robinhood’s Vlad Tenev (both former Under 30 honorees) regained their billionaire status after having fallen out of the ranks.

The budding billionaire has long been fascinated by markets and tech. When he was just 14, Coplan emailed the regional Securities and Exchange Commission office to ask how to create new marketplaces. “I did not get a response, but it’s a really funny email,” he says, grinning playfully as he thinks of his younger self. “It just shows that this stuff takes over a decade of percolating in your mind.”

Two years later, Coplan showed up at the offices of internet startup Genius uninvited after multiple emails of his asking for an internship went ignored. At age 16—at least a decade younger than anyone in that office—he secured his first job after making a memorable impression with his “wild curls” and “encyclopedic knowledge of billionaire tech entrepreneurs.” “If he chooses to become a tech entrepreneur, which seems likely, I have no doubt that we’ll be seeing his name again in the press before long,” Chris Glazek, his manager at the time, wrote in Coplan’s college recommendation letter.

Coplan went on to study computer science at NYU, but dropped out in 2017 to work on various crypto projects that never took off. In 2020, he founded Polymarket to create a solution to the “rampant misinformation” he saw in the world: The company’s first market allowed users to bet on when New York City would reopen amid the pandemic. He soon expanded into elections and pop culture happenings, among other events.

But it didn’t take long for the company to butt heads with regulators. In January 2022, Polymarket paid a $1.4 million fine to the Commodity Futures Trading Commission for offering unregistered markets. It was also ordered to block all U.S. users, but activity on Polymarket skyrocketed particularly during the 2024 U.S. presidential election, with bets totaling $3.6 billion. A week after the election, the FBI raided Coplan's apartment and seized his devices as part of an investigation into a possible violation of this agreement. Shortly after, Coplan posted on his X account that he saw the raid as “a last-ditch effort” from the Biden administration “to go after companies they deem to be associated with political opponents.”

In July, the Department of Justice and CFTC dropped the investigations—after which Sprecher reached out to Coplan for dinner—and less than a week later, Polymarket announced it had acquired CFTC-licensed derivatives exchange QCX to prepare for a compliant U.S. launch. QCX applied to be a federally-registered exchange in 2022—an application that was left dormant for three years before receiving approval less than two weeks before the acquisition was announced. When asked about the timing of the deal, Coplan points to CFTC acting chairwoman Caroline Pham, who President Trump tapped to lead the agency in January. “Caroline deserves a lot of credit for getting every single license that had been paused for no reason approved, as acting chairwoman in less than a year,” he says. Coplan had realized an acquisition might be the only way for Polymarket to legally operate in the U.S. as early as 2021 due to the lengthy federal approval process, a source familiar with the deal told Forbes.

Just two months after the acquisition and days after Donald Trump Jr. joined Polymarket’s advisory board, the company received federal approval to launch in the U.S. (Trump Jr. has also served as a strategic advisor to Polymarket’s main competitor Kalshi since January.)

Polymarket’s rapid rise has drawn critics. Dennis Kelleher, co-founder and CEO of Washington-based financial advocacy group Better Markets, told Forbes in an email that the current administration’s deregulation around prediction markets has unlocked a regulatory “loophole” to enable “unregulated gambling” under the CFTC, “which has zero expertise, capacity or resources to regulate and police these markets.” Kelleher added that with backing from the Trump family “who are directly trying to profit on this new gambling den… the massive deregulation and crypto hysteria will almost certainly end badly for the American people.”

Investors and businesses are scrambling to seize the moment of deregulation. “We had opportunities to invest in events markets earlier, but there was a lot of risk,” Sprecher says, listing the regulatory changes in favor of crypto and prediction markets under the current administration. “This was the moment to invest if we wanted to still be early in the space.”

In the last few months, Trump’s Truth Social and sportsbook FanDuel, as well as cryptocurrency exchanges Crypto.com, Coinbase and Gemini all announced their own plans to offer prediction markets. Robinhood CEO Vlad Tenev said prediction markets, which were integrated into its platform in March, were helping drive record activity for the retail brokerage in its third quarter earnings call.

“People are starting to realize right now that the opportunities are endless,” says Dubin, the billionaire hedge fund veteran who invested in Polymarket earlier this year. He points to sports betting companies, which have been regulated by states as gambling activity and taxed accordingly. States like New York can tax up to 51% of sportsbooks’ revenue, but federally-regulated prediction markets can bypass state laws, avoiding taxes and operating in all 50 states. With the realization that prediction markets could upend the sports betting industry—which brought in $13.7 billion in revenue in 2024—businesses are quickly jumping on board despite pushback from state gambling regulators. In October, both Polymarket and Kalshi secured partnerships with sportsbook PrizePicks and the National Hockey League, and Polymarket announced exclusive partnerships with sportsbook DraftKings and the Ultimate Fighting Championship.

The disruption won’t be limited to sports betting. Alongside its investment, Intercontinental’s tens of thousands of institutional clients including large hedge funds and over 750 third-party providers of data will soon have access to Polymarket data, as it gets integrated into Intercontinental’s products such as indices to better inform investment decisions. It also hopes to work with Polymarket to work on initiatives around tokenization—or converting financial assets into digital tokens on blockchain technology—to allow traders on Intercontinental’s exchanges to trade more flexibly at all hours of the day, Sprecher says. What’s more, in November, Google Finance announced it would integrate Polymarket and Kalshi data into its search results, while Yahoo Finance also announced an exclusive partnership with Polymarket.

Despite flashy investors, partnerships and a record $2.4 billion of trading volume in November, Polymarket has yet to launch in the U.S. or turn a profit. Coplan and his investors have hinted at ways the company could make money one day—selling its data, charging fees to users, launching a cryptocurrency token (similar to Ethereum or Bitcoin)—but decline to confirm any specifics. For now, the only thing that’s certain is the bet Coplan is making on himself. “Going for it and having it not pan out is an infinitely better outcome than living your life as a what if,” he says.

Standing across from the New York Stock Exchange building, Coplan tilts his head up as he watches a massive banner with Polymarket’s logo get hoisted onto the exterior of the building. It’s been five years since founding. One year since the FBI raid. He’s taking it all in. “Against all odds,” the bright blue banner reads, rippling in the wind alongside three American flags protruding from the building.

Source

🙏 Donations Accepted 🙏

If you find value in my content, consider showing your support via:

💳 Stripe:
1) or visit http://thedinarian.locals.com/donate

💳 PayPal
2) Simply scan the QR code below 📲 or Click Here

🔗 Crypto Donations Graciously👇
XRP: r9pid4yrQgs6XSFWhMZ8NkxW3gkydWNyQX
XLM: GDMJF2OCHN3NNNX4T4F6POPBTXK23GTNSNQWUMIVKESTHMQM7XDYAIZT
XDC: xdcc2C02203C4f91375889d7AfADB09E207Edf809A6

Read full Article
See More
Available on mobile and TV devices
google store google store app store app store
google store google store app tv store app tv store amazon store amazon store roku store roku store
Powered by Locals